Chuchalin A. G., Berman B., Lehmacher W.
Explore, 2005
Abstract
Background
Acute bronchitis is a widespread medical problem, and, although predominantly caused by viruses, antibiotics are still prescribed unnecessarily. Therefore, it is of utmost importance to evaluate the use of alternative treatments for acute bronchitis.
Objective
To evaluate the efficacy and safety of a Pelargonium sidoides preparation (EPs 7630 is a registered trademark of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) compared with placebo in patients with acute bronchitis.
Design
Randomized, double-blind, placebo-controlled trial using a design with planned interim analyses.
Setting
Six outpatient clinics.
Patients
One hundred twenty-four adults with acute bronchitis present /=five points, and informed consent.
Intervention
EPs 7630 or placebo (30 drops three times daily) for seven days. Measurements: The primary outcome criterion was the change of BSS on day seven.
Results
The decrease of BSS from baseline to day seven was 7.2 +/- 3.1 points with EPs 7630 (n = 64) and 4.9 +/- 2.7 points with placebo (n = 60). The 95% confidence interval for the difference of effects between the two treatment groups (EPs 7630 minus placebo) was calculated as (1.21, 3.56) showing a significant improvement of EPs 7630 compared with placebo on day seven (P < .0001). For each of the five individual symptoms, rates of complete recovery were considerably higher in the EPs 7630 group. Within the first four days, onset of treatment effect was recognized in 68.8% of patients in the EPs 7630 group compared with 33.3% of patients in the placebo group (P < .0001). Health-related quality of life improved more in patients treated with EPs 7630 compared with placebo-treated patients. Adverse events occurred in 25 of 124 patients (EPs 7630: 15/64 patients, placebo: 10/60 patients). All adverse events were assessed as nonserious.
Conclusions
EPs 7630 was superior in efficacy compared with placebo in the treatment of adults with acute bronchitis. It may therefore offer an effective alternative for acute bronchitis unless antibiotics are clearly indicated.
| PMID: | 16781588 |
|---|---|
| DOI: | 10.1016/j.explore.2005.08.009 |
| Category: | Cold / Flu |
Articles similar to "Treatment of Acute Bronchitis in Adults With a Pelargonium Sidoides Preparation (EPs® 7630): A Randomized, Double-Blind, Placebo-Controlled Trial."
- The significance of Pelargonium Sidoides for Cold / Flu: Efficacy of Proanthocyanidins From Pelargonium sidoides Root Extract in Reducing P. gingivalis Viability While Preserving Oral Commensal S. salivarius. (Bacterial resistance to antibiotics and the disruption of beneficial microbiota are key problems in contemporary medicine and make the search for new, more efficient infection treatment strategies among the most important tasks in medicine...)
- The role of Pelargonium Sidoides in Cold / Flu: Investigation of Antibacterial and Antiinflammatory Activities of Proanthocyanidins From Pelargonium sidoides DC Root Extract. (The study explores antibacterial, antiinflammatory and cytoprotective capacity of Pelargonium sidoides DC root extract (PSRE) and proanthocyanidin fraction from PSRE (PACN) under conditions characteristic for periodontal disease...)
- The impact of Pelargonium Sidoides on Cold / Flu: The Pelargonium Sidoides Extract EPs 7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes. (Pelargonium sidoides is a medical herb and respective extracts are used very frequently for the treatment of respiratory tract infections...)
- The significance of Pelargonium Sidoides for Cold / Flu: The Efficacy of Pelargonium Sidoides in the Treatment of Upper Respiratory Tract Infections in Children With Transient Hypogammaglobulinemia of Infancy. (Transient hypogammaglobulinemia of infancy (THI), defined as prolongation of physiological hypogammaglobulinemia normally seen between the initial 3rd and 6th months of life, is one of the most common immune deficiencies of childhood...)
- The role of Pelargonium Sidoides in Cold / Flu: Efficacy of a Pelargonium Sidoides Preparation in Patients With the Common Cold: A Randomized, Double Blind, Placebo-Controlled Clinical Trial. ( The common cold is a viral infection with symptoms such as sneezing, sore throat, and running nose... EPs represents an effective treatment of the common cold. It significantly reduces the severity of symptoms and shortens the duration of the common cold compared with placebo. The herbal drug is well tolerated.)
- The impact of Pelargonium Sidoides on Cold / Flu: Efficacy and Tolerability of EPs 7630 Tablets in Patients With Acute Bronchitis: A Randomised, Double-Blind, Placebo-Controlled Dose-Finding Study With a Herbal Drug Preparation From Pelargonium Sidoides. (Objective: Acute bronchitis is one of the most frequent health complaints for which patients seek medical advice... This study demonstrated statistically significant and clinically relevant superiority of all three tested dosages of EPs 7630 over placebo. All dosages of EPs 7630 were well-tolerated. Taking into account both efficacy and safety, the results of this study indicate that the 20 mg tablets of EPs 7630 taken three times daily constitute the optimal dose with respect to the benefit-risk ratio.)